Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706557 | 0.97 | TSHR (0.57) | TSHRALDH1A1HSD17B10TDP1HCAR2 | |
| SCHEMBL288698 | 0.85 | TSHR (0.53) | TSHRALDH1A1HSD17B10HCAR2ADRA1A | |
| SCHEMBL3483417 | 0.83 | TSHR (0.52) | TSHRALDH1A1HSD17B10HCAR2ADRA1A | |
| SCHEMBL28905862 | 0.80 | TSHR (0.82) | TSHRALDH1A1HSD17B10TDP1HCAR2 | |
| SCHEMBL22733779 | 0.79 | TSHR (0.43) | TSHRALDH1A1HSD17B10TDP1CHRM2 | |
| SCHEMBL6471616 | 0.79 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1HCAR2 | |
| SCHEMBL36670 | 0.78 | TSHR (0.59) | TSHRALDH1A1HSD17B10HCAR2ADRA1A | |
| SCHEMBL5490374 | 0.78 | TSHR (0.46) | TSHRALDH1A1HSD17B10HCAR2ADRA1A | |
| Propane SCHEMBL22462424 | 0.78 | TSHR (0.46) | TSHRALDH1A1TDP1HCAR2CA12 | |
| SCHEMBL4785172 | 0.77 | TSHR (0.46) | TSHRALDH1A1TDP1HCAR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-0539372-A1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1991011448-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-08 | — | — | WO | disclosed |
| WO-1990001481-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1990-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | SOST, CA1, DUOX2 | TSHR 4386/4885ALDH1A1 1727/4885HSD17B10 189/4885 |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | SOST, CA1, DUOX2 | TSHR 4386/4885ALDH1A1 1727/4885HSD17B10 189/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | TSHR 81/4885ALDH1A1 591/4885HSD17B10 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.